-
Clinical and Experimental Dermatology Jan 2019
Topics: Acyclovir; Adult; Antiviral Agents; Autoimmunity; Chemokines; Child; Dendritic Cells; Herpesvirus 7, Human; Humans; Keratinocytes; Lewis X Antigen; Oligosaccharides; Pityriasis Lichenoides; Sialyl Lewis X Antigen; T-Lymphocytes
PubMed: 29923208
DOI: 10.1111/ced.13694 -
Revista Chilena de Pediatria 2015Pityriasis lichenoides is a benign inflammatory disease of unknown etiology. There are two types of this condition: an acute form (PLEVA = pityriasis lichenoides et... (Review)
Review
INTRODUCTION
Pityriasis lichenoides is a benign inflammatory disease of unknown etiology. There are two types of this condition: an acute form (PLEVA = pityriasis lichenoides et varioliformis acuta) and a chronic one (PLC = pityriasis lichenoid chronica). Both are more common in children and young adults.
OBJECTIVE
To describe a case of PLC, discuss its clinical presentation, diagnosis, treatment and present a review of the literature.
CASE REPORT
A seven-year-old child who presented with recurrent oligosymptomatic episodes of bright erythematous papular lesions in centripetal distribution, which subsided and left behind hypopigmented macules. The biopsy of the lesions confirmed chronic pityriasis lichenoid. During the 3 years of follow-up, multiple treatment regimens were used to reduce exacerbations, resulting in a partial response.
CONCLUSION
PLC is a rare disease that represents a diagnostic and therapeutic challenge to the physician. The diagnosis of this condition is suspected clinically and confirmed by histology. It does not have specific treatment, but it responds well to corticosteroids, antibiotics, immunosuppressants and phototherapy with UVB narrowband (UVBnb). The latter has given the best results. It is important to monitor patients for risk of developing lymphoproliferative disorders.
Topics: Adrenal Cortex Hormones; Aftercare; Anti-Bacterial Agents; Biopsy; Child; Chronic Disease; Humans; Male; Pityriasis Lichenoides; Treatment Outcome; Ultraviolet Therapy
PubMed: 26235693
DOI: 10.1016/j.rchipe.2015.04.024 -
Journal Der Deutschen Dermatologischen... Dec 2023
Topics: Humans; Pityriasis Lichenoides; Methotrexate; Nail Diseases; Nails, Malformed; Pityriasis
PubMed: 37847905
DOI: 10.1111/ddg.15253 -
European Journal of Dermatology : EJD Jun 2023
Topics: Humans; Pityriasis Lichenoides; Brentuximab Vedotin; Lymphoma, T-Cell, Peripheral; Exanthema
PubMed: 37594350
DOI: 10.1684/ejd.2023.4494 -
Dermatologic Therapy May 2020Pityriasis lichenoides (PL) is an uncommon cutaneous disorder. Oral erythromycin is proposed to be effective in treating the disease. Here, we reported 16 pediatric...
Pityriasis lichenoides (PL) is an uncommon cutaneous disorder. Oral erythromycin is proposed to be effective in treating the disease. Here, we reported 16 pediatric patients with PL and systematically reviewed published literatures on erythromycin treatment response in pediatric PL patients, to observe the different treatment response to erythromycin in the pityriasis lichenoides chronica (PLC) and the pityriasis lichenoides et varioliformis acuta (PLEVA) groups. Sixteen patients, 8 with PLC and 8 with PLEVA, were treated with erythromycin. In the PLC group, 25% (n = 2) patients responded to erythromycin, while in the PLEVA group, 87.5% (n = 7) patients responded to erythromycin. The response rate was higher in the PLEVA group than the PLC group (P =.05). No side effect was reported in the 16 patients. A total of 34 children including 16 from our studies were included for further descriptive analysis, in which 12 had PLC and 22 had PLEVA. In the PLC group, 41.7% (n = 5) of patients responded to erythromycin while in the PLEVA group, 90.9 % (n = 20) of patients responded. The response rate was higher in the PLEVA group than the PLC group (P = .004). In conclusion, erythromycin is effective and safe in the treatment of children with PL, and erythromycin was more effective in patients with PLEVA than PLC.
Topics: Child; Erythromycin; Humans; Pityriasis Lichenoides
PubMed: 32174014
DOI: 10.1111/dth.13311 -
Clinical and Experimental Dermatology Dec 2021The classification of pityriasis lichenoides (PL) into pityriasis lichenoides et varioliformis acuta (PLEVA), PL chronica (PLC) and febrile ulceronecrotic...
The classification of pityriasis lichenoides (PL) into pityriasis lichenoides et varioliformis acuta (PLEVA), PL chronica (PLC) and febrile ulceronecrotic Mucha-Habermann disease (FUMHD) is based on both clinical and chronological features. In this retrospective monocentric study, we aimed to investigate the relevance of the classification in routine practice. We enrolled 49 patients (25 female, 24 male; median age 41 years). The lesions were papular in 76% of patients, necrotic in 12% and mixed in 12%. We found three histological patterns: 'classic' (65%), 'lymphomatoid' (13%) and 'mild' (22%). The 'lymphomatoid' pattern was associated with necrotic presentation and the 'mild' pattern with papular lesions (P = 0.01). Among the 27 patients with follow-up, 18% had relapses and 44% had chronic disease. One patient had mycosis fungoides. Neither clinical nor histological findings were correlated with disease progression, and are a reflection of the intensity of epidermal injury rather than of the disease course. The term 'pityriasis lichenoides' should be preferred to the classic PLEVA/PLC/FUMHD classification.
Topics: Adolescent; Adult; Aged; Child; Chronic Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Necrosis; Pityriasis Lichenoides; Recurrence; Retrospective Studies; Severity of Illness Index; Young Adult
PubMed: 34170558
DOI: 10.1111/ced.14818 -
Photodermatology, Photoimmunology &... Sep 2023Pityriasis lichenoides (PL) is a papulosquamous disease affecting both children and adults, for which narrowband-UVB (NB-UVB) phototherapy is regarded as a commonly used... (Observational Study)
Observational Study
INTRODUCTION
Pityriasis lichenoides (PL) is a papulosquamous disease affecting both children and adults, for which narrowband-UVB (NB-UVB) phototherapy is regarded as a commonly used treatment option. The aim of this study was to investigate the efficacy of NB-UVB phototherapy in the management of PL and to compare response rates in pediatric and adult age groups.
MATERIALS AND METHODS
This observational, retrospective study included 20 PL patients (12 pityriasis lichenoides chronica; PLC, 8 pityriasis lichenoides et varioliformis acuta; PLEVA) who failed to respond to other treatment modalities. The data for this study were collected retrospectively from patient follow-up forms in the phototherapy unit.
RESULTS
A complete response (CR) was obtained in all pediatric patients with PL, while 53.8% of adult patients had achieved CR. The mean cumulative dose required to achieve the CR was higher in pediatric patients than adult patients with PL (p < .05). The CR was achieved in 6 (75%) of 8 PLEVA patients, while 8 (66.7%) of 12 PLC patients had reached to CR. The mean number of exposures for patients with PLC to achieve a CR was higher than patients with PLEVA (p < .05). Erythema was the most common adverse effect during phototherapy particularly in 5 (35.7%) of the patients with PL who had achieved CR.
CONCLUSIONS
NB-UVB is an effective and well-tolerated treatment option for PL especially in diffuse types. A higher response can be obtained in children with higher cumulative dose. Patients with PLC may require more exposures for CR than patients with PLEVA.
Topics: Adult; Humans; Child; Pityriasis Lichenoides; Retrospective Studies; Ultraviolet Therapy; Phototherapy; Ultraviolet Rays
PubMed: 37340660
DOI: 10.1111/phpp.12895 -
Dermatologic Therapy May 2020
Topics: Azithromycin; Humans; Pityriasis Lichenoides; Skin
PubMed: 32157758
DOI: 10.1111/dth.13303 -
The British Journal of Dermatology Sep 1953
Topics: Diagnosis, Differential; Humans; Parapsoriasis; Pityriasis; Pityriasis Lichenoides
PubMed: 13081910
DOI: 10.1111/j.1365-2133.1953.tb13754.x -
Italian Journal of Pediatrics Oct 2022Lymphomatoid papulosis (LyP) is a rare condition in pediatrics; LyP histological type D has been reported in only 7 children. The differential diagnosis of LyP in the... (Review)
Review
Type D lymphomatoid papulosis with pityriasis lichenoides et varioliformis acuta-like features in a child with parvovirus infection: a controversial diagnosis in the spectrum of lymphoid proliferations: case report and literature review.
BACKGROUND
Lymphomatoid papulosis (LyP) is a rare condition in pediatrics; LyP histological type D has been reported in only 7 children. The differential diagnosis of LyP in the spectrum of lymphoid proliferation remains controversial.
CASE PRESENTATION
A 6-year-old boy presented to Emergency Department with a 3-week history of an erythematous papulo-vesicular itchy eruption over the submandibular regions, trunk and extremities. History, symptoms and laboratory tests were unremarkable. SARS-CoV-2 antigen was negative. The clinical suspicion of pityriasis lichenoides et varioliformis acuta (PLEVA) was posed, and topical steroids were introduced. One week after, he returned with an extensive painful scaly papulo-erythematous rash, with some ulcerated and necrotic lesions, and fever; therefore the child was hospitalized. Biochemical results were within reference limits, except for high level of C-reactive protein, aspartate aminotransferase, alanine transaminase and bilirubin. Due to a persistently high fever, systemic corticosteroid treatment was administered, with a good clinical response and an improvement of the skin lesions. Anti-PVB-19 Immunoglobulin M was detected. Elevated levels of IL-6, IL-10 and IFN-γ were also recorded. Five days post-admission, most of the lesions had cleared, and the child was discharged. Methotrexate was started, with a positive response. At skin biopsy a "PLEVA-like" pattern was apparent, with a dense, wedge shaped lymphoid infiltrate featuring epidermotropism and morphologically comprising pleomorphic and blastic cells. The pattern of infiltration was highlighted by immunohistochemical stains, which prove the process to feature a CD8+/CD30 + phenotype, the latter being intense on larger cells, with antigenic loss. Polymerase chain reaction for T-cell receptor gamma (TCRG) chain clonality assessment documented a monoclonal peak. A diagnosis of LyP type D was favored.
CONCLUSION
The reported case encompasses most of the critical features of two separated entities-PLEVA and LyP-thus providing further support to the concept of them representing declinations within a sole spectrum of disease. Studying the role of infectious agents as trigger potential in lymphoproliferative cutaneous disorders and detecting novel markers of disease, such as cytokines, could have a crucial impact on pathogenic disease mechanisms and perspective therapies.
Topics: Child; Humans; Male; COVID-19; Lymphomatoid Papulosis; Parvoviridae Infections; Pityriasis Lichenoides; SARS-CoV-2; Cell Proliferation
PubMed: 36307824
DOI: 10.1186/s13052-022-01371-x